Genetics of breast cancer

Mayo Clinic Proceedings

Volumn 72, Issue 1, 1997, Pages 54-65

  Greene, Mark H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIA TELANGIECTASIA; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; COWDEN SYNDROME; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; GENETIC PREDISPOSITION; GYNECOLOGIC CANCER; HUMAN; OVARY CANCER; REVIEW;

EID: 0031412306     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/72.1.54     Document Type: Review

References (99)

1. Colditz GA, Willett WC, Hunter DJ, Stampfer MJ, Manson JE, Hennekens CH, et al. Family history, age, and the risk of breast cancer: prospective data from the Nurses' Health Study. JAMA 1993; 270:338-343
2. Lynch HT, Lynch JF. Breast cancer genetics in an oncology clinic: 328 consecutive patients. Cancer Genet Cytogenet 1986; 22:369371
3. Claus EB, Risch N. Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991:48:232-242
4. Miki Y, Swansen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994:266:66-71
5. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378:789-792
6. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996; 12:333-337
7. Claus EB, Risch NJ, Thompson WD. Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 1990:131:961-972
8. Oilman R, Pike MC, King MC, Casagrande JT, Henderson BE. Familial breast cancer in a population-based series. Am J Epidemiol 1986; 123:15-21
9. Slattery ML. Kerber RA. A comprehensive evaluation of family history and breast cancer risk: the Utah Population Database. JAMA 1993:270:1563-1568
10. Madigan MP, Ziegler RG, BenichouJ, ByrneC, Hoover RN. Proportion of breast cancer cases in the United States explained by wellestablished risk factors. J Natl Cancer Inst 1995; 87:1681-1685
11. Colditz GA, Rosner BA, Speizer FE (Nurses Health Study Research Group). Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst 1996; 88:365-371
12. Brinton LA. Schairer C. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev 1993; 15:66-79
13. Narod SA, Goldgar D, Cannon-Albright L, Weber B, Moslehi R, Ives E, et al. Risk modifiers in carriers of BRCA 1 mutations. Int J Cancer 1995; 64:394-398
14. Anderson DE, Badzioch MD. Bilaterality in familial breast cancer patients. Cancer 1985:56:2092-2098
15. Bernstein JL, Thompson WD, Risch N, Holford TR. The geneticepidemiology of second primary breast cancer. Am J Epidemiol 1992; 136:937-948
16. Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985; 68:99-112
17. Lynch HT, Harris RE, Guirgis HA, Maloney K, Carmody LL, Lynch JF. Familial association of breast/ovarian cancer. Cancer 1978; 41:1543-1549
18. Thompson WD, Schildkraut JM. Family history of gynaecologic cancers: relationships to the incidence of breast cancer prior to age 55. Int J Epidemiol 1991; 20:595-602
19. Peto J, Easton DF, Matthews FE, Ford D, Swerdlow AJ. Cancer mortality in relatives of women with breast cancer: the OPCS Study. IntJ Cancer 1996:65:275-283
20. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77:23182324
21. Easton D, Ford D, Peto J. Inherited susceptibility to breast cancer. Cancer Surv 1993; 18:95-113
22. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250:1684-1689
23. Narod SA, Feunteun J, Lynch HT, Watson P, Conway T, Lynch J, et al. Familial breast-ovarian cancer locus on chromosome 17ql2-q23. Lancet 1991; 338:82-83
24. Easton DF, Bishop DT, Ford D, Crockford GP (Breast Cancer Linkage Consortium). Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993; 52:678-701
25. Ford D, Easton DF. The genetics of breast and ovarian cancer. BrJ Cancer 1995;72:805-812
26. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57:1457-1462
27. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, et al (Breast Cancer Linkage Consortium). An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995; 56:254-264
28. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening. JAMA 1995; 273:535-541
29. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (Breast Cancer Linkage Consortium). Risks of cancer in BRCA1 -mutation carriers. Lancet 1994; 343:692-695
30. Stratton MR, Ford D, Neuhasen S, Seal S, Wooster R, Friedman LS, et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet 1994; 7:103-107
31. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995; 11:428-433
32. Couch FJ, Weber BL (Breast Cancer Information Core). Mutations and polymorphisms in the familial early-onset breast cancer (BRCAl)gem. Hum Mutât 1996; 8:8-18
33. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, et al. The developmental pattern of BRCA1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 1995; 11:17-26
34. Liu CY, Flesken-Nitikin A, Li S, Zeng Y, Lee WH. Inactivation of the mouse BRCA1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev 1996; 10:1835-1843
35. Gudas JM, Nguyen H, Li T, Cowan KH. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 1995; 55:4561-4565
36. Jensen RA, Thompson ME, Jetton TL, Szabo CI, van der Meer R, Helou B, et al. BRCA1 is secreted and exhibits properties of a granin. Nat Genet 1996; 12:303-308
37. Chapman MS, Verma IM. Transcriptional activation by BRCA1 [letter]. Nature 1996; 382:678-679
38. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, et al. BRCA 1 mutations in primary breast and ovarian carcinomas. Science 1994; 266:120-122
39. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996; 13:238-240
40. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, et al. Growth retardation and tumour inhibition by BRCAJ. Nat Genet 1996; 12:298-302
41. L Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q 12-13. Science 1994; 265:2088-2090
42. Thorlacius S, Tryggvadottir L, Olafsdottir GH, Jonasson JG, Ogmundsdottir HM, Tulinius H, et al. Linkage to BRCA2 region in hereditary male breast cancer. Lancet 1995; 346:544-545
43. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996; 13:117-119
44. Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996; 13:120-122
45. Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996; 13:123125
46. Gudmundsson J, Johannesdottir G, Arason A, Bergthorsson JT, Ingvarsson S, Egilsson V, et al. Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet 1996; 58:749-756
47. Struewing JP, Brody LC, Erdos MR, Kase RG, Giambaressi TR, Smith SA, et al. Detection of eight BRCA1 mutations in 10 breast/ ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 1995; 57:1-7
48. Tonin P, Serova O, Lenoir G, Lynch H, Durocher F, Simard J, et al. BRCAl mutations in Ashkenazi Jewish women [letter]. Am J Hum Genet 1995; 57:189
49. Risch N, de Leon D, Ozelius L, Kramer P, Almasy L, Singer B, et al. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet 1995;9:152-159
50. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al. The carrier frequency of the BRCAl 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995; 11:198-200
51. FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, et al. Germ-line BRCAl mutations in Jewish and nonJewish women with early-onset breast cancer. N Engl J Med 1996; 334:143-149
52. Offit K, Gilewski T, McGuire P, Schluger A, Hampel H, Brown K, et al. Germline BRCAl 185delAG mutations in Jewish women with breast cancer. Lancet 1996; 347:1643-1645
53. Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, et al. Novel inherited mutations and variable expressivity of BRCAl alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 1995; 57:1284-1297
54. Berman DB, Wagner-Costalas J, Schultz DC, Lynch HT, Daly M, Godwin AK. Two distinct origins of a common BRCAl mutation in breast-ovarian cancer families: a genetic study of 15 185delAGmutation kindreds. Am J Hum Genet 1996; 58:1166-1176
55. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, et al. Haplotype and phenotype analysis of six recurrent BRCAl mutations in 61 families: results of an international study. Am J Hum Genet 1996; 58:271-280
56. Egan KM, Newcomb PA, Longnecker MP, Trentham-Dietz A, Baron JA, Trichopoulos D, et al. Jewish religion and risk of breast cancer. Lancet 1996; 347:1645-1646
57. Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996; 13:126-128
58. Berman DB, Costalas J, Schultz DC, Grana G, Daly M, Godwin AK. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res 1996; 56:3409-3414
59. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 [letter]. Nat Genet 1996; 14:185-187
60. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, et al. The carrier frequency of the BRCAl 6174delT mutation among Ashkenazi Jewish individuals is approximately 1 % [letter]. Nat Genet 1996; 14:188-190
61. Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996;56:3663-3665
62. Simard J, Tonin P. Durocher F, Morgan K, Rommens J, Gingras S, et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994; 8:392-398
63. Inoue R. Fukutomi T, Ushijima T. Matsumoto Y, Sugimura T, Nagao M. Germline mutation of BRCAI in Japanese breast cancer families. Cancer Res 1995; 55:3521-3524
64. Kerangueven F, Essioux L, Dib A, Noguchi T, Allione F. Geneix J, et al. Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosomes. Oncogene 1995:10:1023-1026
65. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med 1969; 71:747-752
66. Li FP, Fraumeni JF Jr. Prospective study of a family cancer syndrome. JAMA 1982; 247:2692-2694
67. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF Jr, Li FP. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 1991 ; 51:6094-6097
68. Lustbader ED. Williams WR, Bondy ML, Strom S, Strong LC. Segregation analysis of cancer in families of childhood soft-tissuesarcoma patients. Am J Hum Genet 1992; 51:344-356
69. Malkin D. Li FP. Strong LC. Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250:1233-1238
70. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG. Tucker MA, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988:48:5358-5362
71. Prasser J, Elder PA, Condie A. MacFadyen I. Steel CM, Evans HJ. Mutations in p53 do not account for heritable breast cancer: a study in five affected families. Br J Cancer 1991; 63:181-184
72. Warren W, Eeles RA, Ponder BA, Easton DF, Averill D, Ponder MA, et al. No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families. Oncogene 1992; 7:1043-1046
73. Sidransky D, Tokino T. Helzlsouer K, Zehnbauer B, Rausch G. Shelton B, et al. Inherited p53 gene mutations in breast cancer. Cancer Res 1992:52:2984-2986
74. Borresen AL, Andersen TL, Garber J, Barbier-Piraux N, Thorlacius S. Eyfjord J, et al. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 1992; 52:3234-3236
75. Lloyd KM, Dennis M. Cowden's disease: a possible new symptom complex with multiple system involvement. Ann Intern Med 1963; 58:136-142
76. Marra G, Armelao F, Vecchio FM, Percesepe A. Anti M. Cowden's disease with extensive gastrointestinal polyposis. J Clin Gastroenterol 1994: 18:42-47
77. Starink TM, van der Veen JP, Arwert F. de Waal LP, de Lange GG, Gille JJ, et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 1986:29:222-233
78. Brownstein MH. Wolf M, Bikowski JB. Cowden's disease: a cutaneous marker of breast cancer. Cancer 1978; 41:2393-2398
79. Nelen MR, Padberg GW, Peelers EA, Lin AY. van den Helm B. Frants RR, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996; 13:114-116
80. Demeter JG, Waterman NG, Verdi GD. Familial male breast carcinoma. Cancer 1990:65:2342-2343
81. Rosenblatt KA, Thomas DB, McTiernan A, Austin MA, Stalsberg H. Stemhagen A, et al. Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst 1991:83:849-854
82. Sasco AJ, Lowenfels AB. Pasker-de Jong P. Epidemiology of male breast cancer: a meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 1993; 53:538-549
83. Wooster R, Mangion J, Eeles R, Smith S, Dowsett M, Averill D, et al. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet 1992; 2:132-134
84. Lobaccaro JM, Lumbroso S, Belon C, Galtier-Dereure F, Bringer J, Lesimple T. et al. Androgen receptor gene mutation in male breast cancer. Hum Mol Genet 1993; 2:1799-1802
85. Sedgwick RP, Boder E. Ataxia-telangiectasia. In: Vianney de Jong JMB, Vinken PJ, Bruyn GW, Klawans HL, editors. Handbook of Clinical Neurology. Vol 60. New York: Elsevier, 1991: 347-423
86. Swift M, Reitnauer PJ. Morrell D. Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987; 316:1289-1294
87. Pippard EC, Hall AJ, Barber DJ, Bridges BA. Cancer in homozygotes and hétérozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res 1988; 48:2929-2932
88. Borresen AL, Andersen TI, Tretli S, Heiberg A, Moller P. Breast cancer and other cancers in Norwegian families with ataxiatelangiectasia. Genes Chromosomes Cancer 1990:2:339-340
89. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected with ataxia-telangiectasia. N Engl J Med 1991; 325:1831-1836
90. Easton DF. Cancer risks in A-T hétérozygotes. Int J Radiât Biol 1994:66(Suppl6):S177-S182
91. Wooster R. Ford D, Mangion J. Ponder BA. Peto J. Easton DF, et al. Absence of linkage to the ataxia telangiectasia locus in familial breast cancer. Hum Genet 1993; 92:91-94
92. Savitsky K, Bar-Shira A. Gilad S, Rotman G, Ziv Y. Vanagaite L, et al. A single ataxia telangiectasia gene with a product similar to a PI3kinase. Science 1995:268:1749-1753
93. Greenwell PW. Kronmal SL. Porter SE, Gassenhuber J, Obermaier B. Petes TD. TEL!, a gene involved in controlling telomere length in S. cerevisiae, is homologous to the human ataxia telangiectasia gene. Cell 1995; 82:823-829
94. Morrow DM, Tagle DA. Shiloh Y, Collins FS, Hieter P. TELL an S. cerevisiae homolog of the human gene mutated in ataxia telangiectasia, is functionally related to the yeast checkpoint gene MEC1. Cell 1995; 82:831-840
95. Krontiris TG. Minisatellites and human disease. Science 1995; 269:1682-1683
96. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med 1993; 329:517-523
97. Phelan CM, Rebbeck TR. Weber BL, Devilee P. Ruttledge MH, Lynch HT. et al. Ovarian cancer risk in BRCAl carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 1996: 12:309-311
98. Collins FS. BRCAl-lots of mutations, lots of dilemmas [editorial]. N Engl J Med 1996:334:186-188
99. American Society of Clinical Oncology. Genetic testing for cancer susceptibility. J Clin Oncol 1996:14:1730-1736